Aclaris Therapeutics ACRS EPS (Diluted)

EPS (Diluted) at other companies

IncyteINCY

$2.81+37.7%

Corvus PharmaceuticalsCRVS

-$0.15-15.4%

Upstream Bio, Inc.UPB

-$0.73+1.4%

Avalo TherapeuticsAVTX

-$0.83+56.8%

Shattuck Labs, Inc.STTK

-$0.12+50.0%

Cullinan Therapeutics, Inc.CGEM

-$0.69+24.2%

FAQ

What is Aclaris Therapeutics's EPS (diluted)?

Aclaris Therapeutics (ACRS) reported EPS (diluted) of -$0.15 in Q2 2026.

How has Aclaris Therapeutics's EPS (diluted) changed year-over-year?

Aclaris Therapeutics's EPS (diluted) decreased by 15.4% year-over-year, from -$0.13 to -$0.15.

What is the long-term trend for Aclaris Therapeutics's EPS (diluted)?

Over 4 years (2021 to 2025), Aclaris Therapeutics's EPS (diluted) has grown at a -24.5% compound annual growth rate (CAGR), from -$1.63 to -$0.53.

What does EPS (diluted) mean?

Net income divided by the weighted-average number of shares outstanding plus all potentially dilutive securities (stock options, convertibles, warrants). The most conservative EPS measure.